Bristol Myers Squibb Company $BMY Stock Sold by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. reduced its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 0.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 7,200,298 shares of the biopharmaceutical company’s stock after selling 44,332 shares during the quarter. Robeco Institutional Asset Management B.V. owned 0.35% of Bristol Myers Squibb worth $449,299,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the business. Lazard Asset Management LLC lifted its holdings in shares of Bristol Myers Squibb by 23.7% in the first quarter. Lazard Asset Management LLC now owns 1,924,036 shares of the biopharmaceutical company’s stock valued at $116,693,000 after purchasing an additional 368,193 shares in the last quarter. Callan Family Office LLC bought a new position in shares of Bristol Myers Squibb during the second quarter worth about $3,575,000. BlackRock Inc. grew its holdings in shares of Bristol Myers Squibb by 5.1% during the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock worth $10,393,783,000 after buying an additional 8,702,106 shares in the last quarter. Saudi Central Bank raised its position in Bristol Myers Squibb by 90.2% in the 2nd quarter. Saudi Central Bank now owns 142,922 shares of the biopharmaceutical company’s stock valued at $8,235,000 after buying an additional 67,780 shares during the last quarter. Finally, State Street Corp raised its position in Bristol Myers Squibb by 7.3% in the 2nd quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock valued at $6,093,755,000 after buying an additional 7,192,724 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

BMY has been the topic of several research reports. William Blair restated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, October 12th. Morgan Stanley reaffirmed an “underweight” rating and set a $41.00 price target (up from $40.00) on shares of Bristol Myers Squibb in a research note on Wednesday, October 7th. JPMorgan Chase & Co. raised their price target on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Jefferies Financial Group reiterated a “buy” rating and issued a $76.00 price objective on shares of Bristol Myers Squibb in a report on Monday, October 12th. Finally, Cantor Fitzgerald cut their price objective on shares of Bristol Myers Squibb from $59.00 to $53.00 and set a “neutral” rating on the stock in a research report on Thursday, October 8th. Three research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Bristol Myers Squibb currently has a consensus rating of “Moderate Buy” and a consensus price target of $64.88.

Bristol Myers Squibb Price Performance

Shares of NYSE BMY opened at $61.76 on Wednesday. The stock has a market capitalization of $126.15 billion, a price-to-earnings ratio of 13.60, a PEG ratio of 0.29 and a beta of 0.19. The business has a 50-day moving average of $63.39 and a 200-day moving average of $60.28. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $68.64.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%. The business had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. During the same quarter in the previous year, the business earned $1.46 earnings per share. Bristol Myers Squibb’s quarterly revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, sell-side analysts predict that Bristol Myers Squibb Company will post 6.77 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.1%. The ex-dividend date is Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 55.51%.

Insider Buying and Selling at Bristol Myers Squibb

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the business’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the transaction, the senior vice president owned 16,862 shares of the company’s stock, valued at $1,138,185. The trade was a 2.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.05% of the stock is owned by company insiders.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: RBC expects Bristol Myers Squibb to exceed third-quarter revenue estimates, reinforcing optimism ahead of the company’s earnings report. RBC expects a third-quarter revenue beat for Bristol Myers Squibb stock
• Positive Sentiment: Bristol Myers Squibb is scheduled to present new oncology data at ESMO 2026, including results for pumitamig, izalontamab brengitecan (iza-bren), and the Opdivo-Yervoy combination. Positive data could support the company’s pipeline and long-term growth outlook. Bristol Myers Squibb Heads To ESMO 2026 With New Oncology Data
• Positive Sentiment: Analysts and financial commentators continue to highlight BMY’s relatively low valuation, substantial free-cash-flow generation, and dividend yield of approximately 4.3%. Goldman Sachs also upgraded the stock, adding to bullish sentiment. Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? Bristol Myers Squibb Upgraded at The Goldman Sachs Group
• Neutral Sentiment: Investor attention across the pharmaceutical sector is elevated ahead of cancer-drug presentations, with Moderna also attracting buying interest. That broader oncology focus may be helping sentiment toward BMY, although the Moderna catalyst is not directly related to Bristol Myers Squibb. Moderna Jumps While Melanoma Vaccine Data Looms
• Negative Sentiment: The company still faces the challenge of replacing revenue from aging blockbuster medicines. Upcoming ESMO results could either validate its pipeline strategy or increase concerns about future growth. Bristol Myers vs. Eli Lilly: Is BMY’s Deep Valuation Discount Hiding an Opportunity?

Bristol Myers Squibb Profile

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.